Cocaine and cannabinoids antagonize ART efficacy that promotes HIV infection and inflammatory responses at the maternal-fetal interface
About This Grant
PROJECT SUMMARY/ABSTRACT Despite the effectiveness of antiretroviral therapies (ART) in reducing vertical transmission, maternal HIV infection and ART exposure during pregnancy is associated with immune dysregulation in mothers, along with inflammation and significant pathology in the placenta. Compounding these risks is the increasing prevalence of substance abuse among pregnant women and people living with HIV. Compared with the general population, HIV-positive women had higher use of marijuana (15% vs 7%) and cocaine/crack (17% vs 0.1%), and recent findings suggest that 6-18.3% of pregnant women report using illicit drugs throughout gestation. Despite this increase, little is known about the impact of comorbid substance use and HIV/ART on the placenta. In this study we seek to fill this critical knowledge gap by elucidating the mechanisms driving placental dysfunction in pregnant women living with HIV with comorbid substance use and examine how cocaine and/or cannabis use may exacerbate viral infectivity, inflammation, and ART efficacy at the maternal- fetal interface. We hypothesize cocaine and cannabis polysubstance use antagonize placental ART transport and metabolism through PXR signaling, which promotes HIV replication, inflammatory responses, and placental abnormalities associated with adverse maternal and fetal outcomes. We will address this by evaluating: pharmacologic mechanisms by which comorbid substance use and HIV alter ART placental efficacy (Aim 1), immunologic and virologic mechanisms underlying effects of comorbid substance use and HIV/ART on the placenta (Aim 2), and evaluate whether HIV, ART and/or comorbid substance use is associated with dysfunction and inflammation in placentae and maternal blood from HIV (+) and (-) pregnancies (Aim 3).
Grant Summary
Cocaine and cannabinoids antagonize ART efficacy that promotes HIV infection and inflammatory responses at the maternal-fetal interface is a NIDA - National Institute on Drug Abuse grant providing up to $683K for university, nonprofit, healthcare org. Applications are due 2031-02-28 (open). Check eligibility and apply with FindGrants.
Not quite the right fit?
Search 9,000+ open grants, or get matches ranked for your organization — free.
Focus Areas
Eligibility
How to Apply
Up to $683K
2031-02-28
- 1Confirm your organization is eligible for Cocaine and cannabinoids antagonize ART efficacy that promotes HIV infection and inflammatory responses at the maternal-fetal interface from NIDA - National Institute on Drug Abuse, checking organization type, location, and any population or project requirements.
- 2Gather the required documents and information, including your organization details, project plan, and budget figures.
- 3Draft your application narrative and budget addressing the funder's priorities and review criteria. FindGrants can draft each section for you to review and edit.
- 4Review every section against the requirements checklist, then export a submission-ready application pack and submit it to NIDA - National Institute on Drug Abuse before the deadline.
Don't want to draft it yourself?
We'll draft the complete application against NIDA - National Institute on Drug Abuse's requirements, run a quality review, and email you a submission-ready PDF plus an editable Word doc within 5 business days. Most orders deliver in 24-48 hours. Flat $399, any grant size.
AI Requirement Analysis
Detailed requirements not yet analyzed
Have the NOFO? Paste it below for AI-powered requirement analysis.
Cocaine and cannabinoids antagonize ART efficacy that promotes HIV infection and inflammatory responses at the maternal-fetal interface: Frequently Asked Questions
Who is eligible for the Cocaine and cannabinoids antagonize ART efficacy that promotes HIV infection and inflammatory responses at the maternal-fetal interface?
Cocaine and cannabinoids antagonize ART efficacy that promotes HIV infection and inflammatory responses at the maternal-fetal interface is offered by NIDA - National Institute on Drug Abuse and is generally open to university, nonprofit, healthcare org. It is open to organizations nationwide unless the funder specifies otherwise. Review the specific eligibility terms before applying, since funders set their own requirements around organization type, location, and the population or project being served.
How much funding does the Cocaine and cannabinoids antagonize ART efficacy that promotes HIV infection and inflammatory responses at the maternal-fetal interface provide?
Cocaine and cannabinoids antagonize ART efficacy that promotes HIV infection and inflammatory responses at the maternal-fetal interface provides up to $683K per award from NIDA - National Institute on Drug Abuse. Actual award sizes depend on the scope of your project, available program funds, and the number of applicants, so build a budget that reflects realistic, allowable costs rather than the maximum figure.
When is the Cocaine and cannabinoids antagonize ART efficacy that promotes HIV infection and inflammatory responses at the maternal-fetal interface deadline?
Applications for Cocaine and cannabinoids antagonize ART efficacy that promotes HIV infection and inflammatory responses at the maternal-fetal interface are due 2031-02-28 (open). Because deadlines can change, verify the date with the funder, NIDA - National Institute on Drug Abuse, and give yourself enough time to prepare a complete, competitive application before the close date.
How do you apply for the Cocaine and cannabinoids antagonize ART efficacy that promotes HIV infection and inflammatory responses at the maternal-fetal interface?
To apply for Cocaine and cannabinoids antagonize ART efficacy that promotes HIV infection and inflammatory responses at the maternal-fetal interface, confirm your eligibility, gather the required documents, and prepare a narrative and budget that address the funder's priorities. FindGrants guides you step by step and can draft each section, then exports a submission-ready application pack for this grant from NIDA - National Institute on Drug Abuse.